The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis
Value in Health · 2023-02 · 26 (2) · 216-225
DOI: 10.1016/j.jval.2022.08.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2023-02. Verfasst von Stacey Kowal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc, South San Francisco, CA, USA. Electronic address: kowal.stacey@gene.com. Hauptthemen laut MEDLINE: Health Equity, COVID-19. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech.
Abstract (Originalsprache)
OBJECTIVES: We conducted a distributional cost-effectiveness analysis (DCEA) to evaluate how Medicare funding of inpatient COVID-19 treatments affected health equity in the United States. METHODS: A DCEA, based on an existing cost-effectiveness analysis model, was conducted from the perspective of a single US payer, Medicare. The US population was divided based on race and ethnicity (Hispanic, non-Hispanic black, and non-Hispanic white) and county-level social vulnerability index (5 quintile groups) into 15 equity-relevant subgroups. The baseline distribution of quality-adjusted life expectancy was estimated across the equity subgroups. Opportunity costs were estimated by converting total spend on COVID-19 inpatient treatments into health losses, expressed as quality-adjusted life-years (QALYs), using base-case assumptions of an opportunity cost threshold of $150 000 per QALY gained and an equal distribution of opportunity costs across equity-relevant subgroups. RESULTS: More socially vulnerable populations received larger per capita health benefits due to higher COVID-19 incidence and baseline in-hospital mortality. The total direct medical cost of inpatient COVID-19 interventions in the United States in 2020 was estimated at $25.83 billion with an estimated net benefit of 735 569 QALYs after adjusting for opportunity costs. Funding inpatient COVID-19 treatment reduced the population-level burden of health inequality by 0.234%. Conclusions remained robust across scenario and sensitivity analyses. CONCLUSIONS: To the best of our knowledge, this is the first DCEA to quantify the equity implications of funding COVID-19 treatments in the United States. Medicare funding of COVID-19 treatments in the United States could improve overall health while reducing existing health inequalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genentech, Inc, South San Francisco, CA, USA. Electronic address: kowal.stacey@gene.com.
- Genentech, Inc, South San Francisco, CA, USA.
- Centre for Health Economics, University of York, York, England, UK.
Förderung
- Genentech
Zitieren
APA
Kowal, S., Ng, C. D., Schuldt, R., Sheinson, D., & Cookson, R. (2023). The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis. Value in Health, 26(2), 216-225. https://doi.org/10.1016/j.jval.2022.08.010
Vancouver
Kowal S, Ng CD, Schuldt R, Sheinson D, Cookson R. The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis. Value in Health. 2023;26(2):216-225. doi:10.1016/j.jval.2022.08.010
BibTeX
@article{Kowal2023,
author = {Kowal, Stacey and Ng, Carmen D and Schuldt, Robert and Sheinson, Daniel and Cookson, Richard},
title = {The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis},
journal = {Value in Health},
year = {2023},
volume = {26},
number = {2},
pages = {216--225},
doi = {10.1016/j.jval.2022.08.010}
}
EUVIMED